Delivery Order SPE2DB22D2214-SPE2DB24FS4PM

Award Date 4/26/24
Potential Completion Date 4/29/24
Potential Value $5.4K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,325.64 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of September 3, 2024 and was awarded on August 30, 2024. It is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, to provide GILENYA 0.5 MG CAPSULE 30S. The contract has a ceiling value of $2,936.60 and a period of performance through March 26, 2024. Amerisourcebergen Drug Corp is the prime contractor on this award, which is not designated as a set-aside contract. In addition to this delivery order,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product. The contract has a ceiling value of $35,454.11 and a completion date of March 6, 2024. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor and this award is part of a larger Indefinite Delivery Contract...
This federal contract award is for the delivery of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $20,973.09 and an ultimate completion date of November 29, 2023. It is a firm fixed-price delivery order contract awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not designated as a set-aside. Amerisourcebergen holds a...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed-price delivery order contract valued at $12,076.95 for the supply of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of April 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00, which serves as Amerisourcebergen Drug Corp's primary contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $83,960.83 firm fixed-price delivery order is for the supply of GILENYA 0.5 MG CAPSULE 30S, a prescription medication. The contract has an ultimate completion date of June 27, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,782.20 firm fixed-price delivery order is for the supply of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product, with an ultimate completion date of November 7, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award is for the delivery of Gilenya 0.5 mg Capsule 30s to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $8,878.38, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 3, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of September 4, 2024. This contract is not associated with a set-aside designation. AmerisourceBergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,246.55 Firm Fixed Price Delivery Order contract is for the provision of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of October 11, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $20,258.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of GILENYA 0.5 MG CAPSULE 30S. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of August 2, 2024. Amerisourcebergen has been awarded multiple indefinite delivery contracts (IDCs) by the DLA and other federal agencies, such as the Department of Justice Federal Bureau of...
  • SPE2DB22D2214
    Indefinite Delivery Contract
  • SPE2DB22D2214-SPE2DB24FS4PM
    Delivery Order

This federal contract award is for the delivery of GILENYA 0.5 MG CAPSULE 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $5,428.89 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of April 29, 2024 and was awarded on April 26, 2024.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract award reviewed does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 12:32 PM